Don’t miss this live conversation with Sabina from GLPwinner.com as she joins us to discuss the next legal battlefield for compounds: states. We also discuss how the federal legislation is likely a messaging bill to help advance state agendas.

This episode delivers a deep, unfiltered breakdown of the latest Retatrutide data—showing weight-loss results that approach and even rival bariatric surgery—while exposing the growing battle over access, pricing, and Lilly’s push to classify the drug as a biologic. It also examines the exploding gray market, new telehealth outcomes, and why the future of obesity medicine will depend on protecting patient access to these life-changing treatments.

In this livestream, Dave breaks down new phase 3 retatrutide data, carefully contrasting idealized trial “efficacy estimate” numbers with more realistic “treatment regimen” outcomes, and explores what this means for real-world obesity care, dosing, and future multi-pathway combinations. He then shifts to news on high-dose Wegovy, safety concerns and fast-tracking of the oral GLP-1 orforglipron, and a detailed critique of the proposed Safe Drug Act of 2025, urging viewers to oppose it via a petition at otplinks.com because of its potential impact on access to compounded obesity medications.

This week’s episode dives into one of the most exciting moments we’ve seen yet in obesity medicine. We break down brand-new data on Wave Life Sciences’ single-injection therapy—showing visceral fat loss, total fat reduction, and even increased lean muscle—marking a major shift toward “quality of weight loss,” not just the number on the scale. We also explore the latest on amylin drugs from Novo Nordisk and Eli Lilly, updates on oral GLP-1s like orforglipron and alaniglipron, and why maintenance therapies are becoming the next big frontier. Dave also covers the ongoing counterfeit Ozempic problem and what patients need to look for. It’s a packed episode with everything you need to understand where obesity treatment is headed next.

This week’s On The Pen podcast unpacked major developments in obesity and metabolic health. New data from Harvard and Mass General suggest that nearly 70% of U.S. adults may qualify as having obesity when waist circumference is added to BMI. Dave also covered an emerging oral triple agonist with breakthrough absorption rates, promising early results from Fractal Health showing weight maintenance after GLP-1 discontinuation, and recent cash-pay price reductions for Zepbound. The episode also revisited Novo Nordisk’s Alzheimer’s trial, clarifying why the results weren’t the final word on GLP-1s in cognitive disease. Dave closed with personal insights on hunger signals after switching medications, plus updates on access, tools, and upcoming savings programs.

Dave opens the episode with gratitude during a difficult week, sharing how the OTP community’s support has helped him stay grounded after losing his 60,000-follower TikTok account overnight. He then breaks down major new data in obesity and diabetes medicine—including updates on Alzheimer’s trials, amicretin, tirzepatide, and orforglipron—emphasizing what these developments mean for patients and the future of personalized metabolic care.

How much will GLP-1 meds be under Trumps new plan? On this week's podcast, Dave discusses the future of obesity medicine and the current state of branded and compounded GLP-1 meds.

Zepbound and Wegovy price lead the charge in breaking news today, as well as Novo Nordisk and Pfizer’s fight over Metsera.

Eli Lilly just dropped their Q3 2025 earnings, and it’s clear the GLP-1 era has entered a new phase. Lilly now controls 6 out of 10 GLP-1 prescriptions in the U.S., driven by massive demand for Zepbound, Mounjaro, and soon Orforglipron, the first oral GLP-1 pill for obesity that could hit the market as early as 2026. In this episode of On The Pen, we break down the key takeaways from Lilly’s call: • Zepbound’s meteoric growth and how 40% of new prescriptions now flow through Lilly Direct • Orforglipron’s global submissions for obesity and type 2 diabetes with a possible priority FDA review that could mean approval in as little as 1 to 2 months • Retatrutide’s next trials for obesity and osteoarthritis pain • What Dave Ricks really meant when he said a $100 GLP-1 pill would “stifle innovation” • The growing tension between innovation and affordability in obesity medicine This isn’t just a numbers story. It’s about access, cost, and the fight for who gets to afford staying healthy.

This Week Dave breaks down: The UK’s massive MHRA raid on a counterfeit GLP-1 operation and what it reveals about access gaps driving patients to unsafe sources. Why Cigna’s promise to help patients sent their stock soaring and how PBMs like Express Scripts profit while pretending to reform. Innovent’s Mazdutide showing stronger weight loss than semaglutide and what that means for global obesity drug innovation. Terns Pharmaceuticals scaling back its metabolic programs after modest GLP-1 results, proof of how hard it is for small biotech to survive this race. New Lancet data confirming semaglutide’s heart protection, even without diabetes. Whistleblower allegations from Washington State involving Aequita Pharmacy and Mochi Health, claims that raise new questions about compounding safety. Ro’s RAID-FN Food Noise scale, the first scientifically validated tool to measure something patients have felt for years but science couldn’t define.

On The Pen brings you 7 short interviews with a who's who in Obesity Care from HLTH 2025 in Las Vegas! From microdosing glp-1peptides to longevity peptides, some of the most exciting faces in the space share their insights!

Joining me today is Max Beyer, pharma reporter at Endpoints News and one of the sharpest voices covering pharma policy, pricing, and the biotech world. If you’ve seen the viral clip from Trump’s press event where he promised to drop the price of the so-called ‘fat shot’ to $150, that moment started with Max’s question. His work at Endpoints has been ahead of the curve on everything from Most Favored Nation drug pricing to the political tug-of-war that’s shaping the future of GLP-1 access in America. Max isn’t just writing about the drug industry, he’s talking to the people moving it, and today, we get to hear what it was like to be in the room when a single question shook the global obesity market.

In this episode: What the FDA warning really means for Wegovy, Ozempic, and Zepbound users Why an OAI classification matters — and how it could affect GLP-1 access How the FDA oversight system protects patients (and where it fails) Why compounded GLP-1 medications exist in the first place The bigger picture: access, safety, and patient rights

This episode of *On The Pen* dives into three major developments shaping obesity care: Fractyl Health’s groundbreaking GLP-1 + GIP gene therapy, Dr. Mehmet Oz’s hints about potential Medicare coverage for GLP-1s, and the federal court ruling on retatrutide that could redefine compounded access. Together, these stories reveal how science, policy, and regulation are colliding to decide the future of obesity treatment.

joins Dave to discuss what it's like to publicly battle weight and addiction, and find peace in front of a watching world.

NFL lineman, Ike Boetgger, joins Dave as his first "in-studio" guest to discuss the power of individualized medicine en route achieving his healthiest version of himself.

This week, Dave knapp interviews Fractyl, CEO, Harith Rajagopalan and discusses a new treatment that may allow patients to maintain their weight loss post GLP-1.

Christopher Lafron AKA Airsoft Fatty talks about his weight loss and shares his takes on obesity. (Language warning) Dr. Leslie Golden shares her obesity journey from her perspective as a physician and talks obesity medicine advocacy. Ali from Fit Flavor Fun shares tips for newbies on GLP-1 meds!

Pfizer buys Metsera, and Dave covers the compound Tirzepatide threat landscape